Molecular probes for imaging myelin
A molecular probe for use in the detection of myelin in a subject includes a compound having the general formula selected from the group consisting of: formula (I), and pharmaceutically acceptable salts thereof.
1. A method of detecting myelin in vivo in a subject's tissue, the method comprising:
(i) administering to the subject a molecular probe including a compound having the general formula selected from the group consisting of:
wherein n is an integer from 1 to 10; A, B each independently represent CR′ 2 , O, S, NH, CH 2 CH 2 , CH═CH; R 1 , R 2 , R′, and Z each independently represent H, alkyl, alkenyl, alkynyl and/or an aryl group; X and Y each independently represent
wherein R″=H, alkyl, alkenyl, alkynyl or an aryl group; and pharmaceutically acceptable salts thereof; and
(ii) detecting the location, distribution, and/or amount of the compound that is bound to the myelin to detect the myelin in the tissue.
2. The method of claim 1 , wherein R 1 ═R 2 .
3. The method of claim 1 , wherein A=B.
4. The method of claim 1 , wherein X═Y.
5. The method of claim 1 , the molecular probe further comprising a radiolabel.
6. The method of claim 1 , the molecular probe further comprising a magnetic resonance contrast agent that is bound to the molecular probe to facilitate or enhance magnetic resonance imaging of the molecular probe.
7. The method of claim 1 , the molecular probe including a compound having the general formula:
wherein n is an integer from 1 to 10; A, B each independently represent CR′ 2 , O, S, NH, CH 2 CH 2 , CH═CH; R 1 , R 2 , R′, and Z each independently represent H, alkyl, alkenyl, alkynyl and/or an aryl group; X and Y each independently represent
wherein R″=H, alkyl, alkenyl, alkynyl or an aryl group; and pharmaceutically acceptable salts thereof.
8. The method of claim 7 comprising the formula:
and pharmaceutically acceptable salts thereof.
9. The method of claim 7 , the molecular probe including a compound having the formula:
and pharmaceutically acceptable salts thereof.
10. The method of claim 1 , the molecular probe including a compound having the general formula:
wherein n is an integer from 1 to 10; R 1 , R 2 , R′, and Z each independently represent H, alkyl, alkenyl, alkynyl and/or an aryl group; X and Y each independently represent
wherein R″=H, alkyl, alkenyl, alkynyl or an aryl group; and pharmaceutically acceptable salts thereof.
11. The method of claim 1 , wherein the location, distribution, and/or amount of the compound is detected using in vivo imaging modality comprising a near-infrared fluorescence imaging modality.
12. The method of claim 1 , the in vivo imaging modality comprising a fluorescence molecular tomography imaging modality.
13. The method of claim 1 , further comprising the step of administering the molecular probe to the subject parenterally.
14. A method of detecting myelin in vivo in a subject's tissue, the method comprising:
(i) administering to the subject a molecular probe including a compound having the general formula of:
wherein n is an integer from 3 to 10; A, B each independently represent CR′ 2 , O, S, NH, CH 2 CH 2 , CH═CH; R 1 , R 2 , R′, and Z each independently represent H, alkyl, alkenyl, alkynyl and/or an aryl group; X and Y each independently represent
wherein R″=H, alkyl, alkenyl, alkynyl or an aryl group; and pharmaceutically acceptable salts thereof; and
(ii) detecting the location, distribution, and/or amount of the compound that is bound to the myelin to detect the myelin in the tissue.
15. The method of claim 14 , wherein R 1 ═R 2 .
16. The method of claim 14 , wherein A=B.
17. The method of claim 14 , wherein X═Y.
18. The method of claim 14 , the molecular probe further comprising a radiolabel.
19. The method of claim 14 , the molecular probe further comprising a magnetic resonance contrast agent that is bound to the molecular probe to facilitate or enhance magnetic resonance imaging of the molecular probe.
20. The method of claim 14 , the molecular probe including a compound having the formula:
and pharmaceutically acceptable salts thereof.
21. The method of claim 14 , wherein the location, distribution, and/or amount of the compound is detected using an in vivo imaging modality comprising a near-infrared fluorescence imaging modality.
22. The method of claim 14 , further comprising the step of administering the molecular probe to the subject parenterally.